https://www.selleckchem.com/pr....oducts/netarsudil-ar
After 3months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy. Patients with prior treatment failure or partial efficacy to onabotulinumtoxinA respond to anti-CGRP mAbs. After 3 months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy. Analyze the effect of paternal immunotherapy treatment (PIT) in primary and secondary unexplained recurrent spontaneous abortion (URSA) and unexplained infertility (UI). A retrospective study anal
Like
Comment
Share
